Dutch experience demonstrates effective benchmarking of biosimilar use in health systems

31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...

Read more →

Dutch health minister threatens to name and shame pharma over prices

28 August 2019 - In an unusual move, the Netherlands health minister wrote an open letter to the pharmaceutical industry ...

Read more →

Dutch minister warns big pharma to come clean on drugs prices

27 August 2019 - Health minister Bruno Bruins has warned the pharmaceuticals industry that he considers the way drugs firms ...

Read more →

Implementation of “coverage with evidence development” drug approval strategies found lacking

15 July 2019 - Lessons from early deployments in The Netherlands. ...

Read more →

Taxpayers are funding expensive drug development, report says

10 May 2019 - The Dutch government invests tens of millions of euros every year in small biotech companies which ...

Read more →

Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?

23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines.  ...

Read more →

Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes

8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...

Read more →

Conditional financing of drugs in the Netherlands: past, present, and future—results from stakeholder interviews

8 April 2019 - It is long known that managed entry agreements may offer decision makers valuable policy options to ...

Read more →

AbbVie's massive Humira discounts are stifling Netherlands biosimilars

2 April 2019 - Could a drug's price ever be too low? That’s what some market-watchers are asking in the ...

Read more →

Dutch join backlash at expensive drugs by making their own

8 March 2019 - In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass ...

Read more →

Determining the comparative value of pharmaceutical risk-sharing policies in non–small cell lung cancer using real-world data

2 March 2019 - Risk-sharing arrangements can be used to mitigate uncertainty about the value of a drug by sharing the ...

Read more →

Pharma lashes out at the Netherlands over drug pricing policies

6 November 2019 - As the Dutch government gets more aggressive about controlling the cost of medicines, the pharmaceutical industry ...

Read more →

Novartis and Vertex battle the Netherlands government over pricing

4 February 2019 - Two large drug makers are squaring off against the Netherlands as drug pricing increasingly becomes a ...

Read more →

Big pharma firms criticise Dutch campaign to slash drug prices

5 February 2019 - Foreign pharmaceuticals companies in the Netherlands say they are ‘concerned’ that the government is undermining the ...

Read more →

Minister to ‘talk to Novartis’ after five-fold cancer drug price hike

10 January 2019 - Health minister Bruno Bruins is planning to talk to Swiss pharmaceuticals giant Novartis this week about ...

Read more →